- Home
- MVST vs INBX Comparison
MVST vs INBX Comparison
Compare MVST & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | INBX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MVST | INBX |
|---|---|---|
| Price | $2.87 | $73.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 185.7K |
| Earning Date | 11-10-2025 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $444,504,000.00 | $1,400,000.00 |
| Revenue This Year | $24.19 | $563.00 |
| Revenue Next Year | $17.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $1.09 | $10.81 |
| 52 Week High | $7.12 | $94.57 |
Technical Indicators
Market Signals| Indicator | MVST | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 45.59 |
| Support Level | $2.78 | $71.25 |
| Resistance Level | $3.16 | $82.16 |
| Average True Range (ATR) | 0.22 | 4.92 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 11.62 | 30.30 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.